Sumitomo Pharma Oncology, Inc.
10 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Sumitomo Dainippon Pharma Oncology, Inc. (to 2022)
0
Ending by 2030
Sep 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 23, 2027The maintenance fee for Predicting response to alvocidib by mitochondrial profiling (US 10,357,488) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
- 1 fee due Feb 1, 2027The maintenance fee for Compositions comprising PKM2 modulators and methods of treatment using the same (US 11,712,433) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
- 2 fees due Mar 5 to 24, 2027 · next Mar 5
- 1 fee due May 12, 2027The maintenance fee for PKM2 modulators and methods for their use (US 10,472,328) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
- 2 fees due Aug 18 to 25, 2027 · next Aug 18
- 1 fee due Oct 21, 2027The maintenance fee for Predicting response to alvocidib by mitochondrial profiling (US 10,624,880) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,901,120 | Substituted N-PHENYLPYRIMIDIN-2-Amine Analogs as Inhibitors of the Axl Kinase In force · High confidence | In force | High confidence | |
| US 9,394,257 | PKM2 modulators and methods for their use In force · From the USPTO record | In force | From the USPTO record | |
| US 10,207,996 | PKM2 Modulators and Methods for Their Use In force · Medium confidence | In force | Medium confidence | |
| US 10,472,328 | PKM2 modulators and methods for their use In force · From the USPTO record | In force | From the USPTO record | |
| US 10,766,865 | PKM2 modulators and methods for their use In force · From the USPTO record | In force | From the USPTO record | |
| US 10,357,488 | Predicting response to alvocidib by mitochondrial profiling In force · From the USPTO record | In force | From the USPTO record | |
| US 10,624,880 | Predicting response to alvocidib by mitochondrial profiling In force · From the USPTO record | In force | From the USPTO record | |
| US 9,758,539 | Alvocidib prodrugs having increased bioavailability In force · From the USPTO record | In force | From the USPTO record | |
| US 10,259,835 | Alvocidib Prodrugs Having Increased Bioavailability In force · Medium confidence | In force | Medium confidence | |
| US 10,562,925 | Alvocidib prodrugs having increased bioavailability In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 24: 10 patents in force now held by others · 6 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 2 abandoned · 11 no status recorded